Retinoic acid, an analogue of vitamin A, is known to be teratogenic in laboratory animals
and has recently been implicated in a few clinical case reports. To study the human …

Improvements in medical interventions for people with Down's syndrome have led to a
substantial increase in their longevity. Diagnosis and treatment of neurological complications are …

Down syndrome (DS), or trisomy 21, is a common disorder associated with several complex
clinical phenotypes. Although several hypotheses have been put forward, it is unclear as to …

Down syndrome (DS) is characterized by increased mortality rates, both during early and
later stages of life, and age‐specific mortality risk remains higher in adults with DS compared …

There is evidence to suggest that certain shared features exist in the pathogenesis of vascular
disease and Alzheimer disease (AD) in the general population. In Down syndrome (DS) …

Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer
disease (AD) by the age of 40 years. This association is partially due to overexpression …

Two markers of neuronal plasticity were used to compare the response of the human central
nervous system to neuronal loss resulting from Alzheimer's disease with the response of …

This chapter reviews the neurological phenotype of Down syndrome (DS) in early
development, childhood, and aging. Neuroanatomic abnormalities in DS are manifested as …

Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to
play a critical role in the development of AD neuropathology. The overexpression of the gene …

Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down
syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer’s …